This article is more than 5 years old. Information may no longer be current.

AzaSite commercially available in United States for treating conjunctivitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — AzaSite, a topical treatment for bacterial conjunctivitis, is now commercially available in the United States from Inspire Pharmaceuticals, the company announced in a press release.

The drug was developed by InSite Vision and is a formulation of azithromycin 1% delivered via InSite's patented DuraSite drug delivery system, according to a press release from InSite.

Inspire licensed the rights from InSite for commercializing the drug for ocular infections in the United States and Canada in February, and the U.S. Food and Drug Administration approved it for treating bacterial conjunctivitis in April, according to the release.

AzaSite offers the lowest dosing regimen for treating bacterial conjunctivitis: one drop twice-a-day for 2 days followed by one drop once-a-day for 5 days, for a total of nine drops per affected eye, according to Inspire's press release.

Inspire estimates revenues from U.S. sales of AzaSite to total $30 million to $45 million in 2008, the release said.